Record-Breaking Revenue Growth
SI-BONE delivered worldwide revenue growth of approximately 22% in Q2 2025. U.S. revenue, which accounts for 95% of the business, grew approximately 23%, supported by a 25% increase in procedure volumes.
Positive Profitability Milestones
The company achieved its third consecutive quarter of positive adjusted EBITDA and reached cash flow breakeven well ahead of the original timeline.
Surge in Physician Engagement
A record 1,440 U.S. physicians performed procedures using SI-BONE products in Q2 2025, representing an increase of 25% over the prior year period.
Expansion of International Markets
Successful launch of iFuse TORQ in Europe, with expectations of accelerated adoption and growth across international markets.
Strong Gross Margin Performance
Gross margin was 79.8%, expanding by 80 basis points year-over-year, driven by actions to improve manufacturing and supply chain efficiencies.